Department of Internal Medicine, Research Institute for Medical Science, Chonbuk National University Medical School and Hospital, Jeonju , South Korea.
Intervirology. 2010;53(3):146-53. doi: 10.1159/000274975.
The authors compared the efficacies and tolerabilities of pegylated interferon-alpha2a (PEG-IFN-alpha2a) + ribavirin and pegylated interferon-alpha2b (PEG-IFN-alpha2b) + ribavirin for the initial treatment of chronic hepatitis C.
A total of 126 treatment-naive patients (29.4% genotype 1, 70.6% genotype non-1) were treated with PEG-IFN-alpha2a 180 microg/week (group A, n = 79) or PEG-IFN-alpha2b 1.5 microg/kg/week (group B, n = 47) with ribavirin (800 mg/day for genotype non-1 or 1,000-1,200 mg/day for genotype 1) for 24 (genotype non-1) or 48 weeks (genotype 1).
End-of-treatment virologic response, sustained virologic response, and biochemical response were not significantly different in groups A and B (84.8 vs. 89.4%, 70.9 vs. 72.3%, and 70.9 vs. 74.5%, respectively; p > 0.05). In patients with the HCV genotype 1 or non-1, treatment responses were not significantly different. Multivariate analysis showed that HCV genotype only was an independent factor that affected sustained virologic response (p = 0.048). The proportions of treatment discontinuations in groups A and B were similar (10.1 vs. 10.6%; p = 1.000).
PEG-IFN-alpha2a or PEG-IFN-alpha2b + ribavirin combination therapies showed similar efficacies and tolerabilities as initial treatments for chronic hepatitis C.
作者比较了聚乙二醇干扰素-α2a（PEG-IFN-α2a）+利巴韦林和聚乙二醇干扰素-α2b（PEG-IFN-α2b）+利巴韦林在慢性丙型肝炎初始治疗中的疗效和耐受性。
共 126 例初治患者（29.4%基因型 1，70.6%基因型非 1）接受 PEG-IFN-α2a 180μg/周（A 组，n=79）或 PEG-IFN-α2b 1.5μg/kg/周（B 组，n=47）治疗，联合利巴韦林（基因型非 1 为 800mg/天，基因型 1 为 1000-1200mg/天）治疗 24 周（基因型非 1）或 48 周（基因型 1）。
A 组和 B 组的治疗结束时病毒学应答、持续病毒学应答和生化应答无显著差异（84.8%比 89.4%，70.9%比 72.3%和 70.9%比 74.5%；p＞0.05）。在基因型 1 或非 1 的患者中，治疗反应无显著差异。多变量分析显示，HCV 基因型是影响持续病毒学应答的独立因素（p=0.048）。A 组和 B 组的停药比例相似（10.1%比 10.6%；p=1.000）。
PEG-IFN-α2a 或 PEG-IFN-α2b+利巴韦林联合治疗方案作为慢性丙型肝炎的初始治疗具有相似的疗效和耐受性。
